## UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 26, 2015

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Antares Pharma, Inc.

File No. 1-32302 - CF#32383

Antares Pharma, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on July 12, 2012.

Based on representations by Antares Pharma, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1 through April 15, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary